Skip to content

Study · Animal study (in vivo) · mouse · 2021

12 results

Dulaglutide Alone and in Combination with Empagliflozin Attenuate Inflammatory Pathways and Microbiome Dysbiosis in a Non-Diabetic Mouse Model of NASH.

Hupa-Breier KL, Dywicki J, Hartleben B, Wellhöner F, Heidrich B, Taubert R, Mederacke YE, Lieber M, Iordanidis K, Manns MP, Wedemeyer H, Hardtke-Wolenski M, Jaeckel E

Biomedicines30 Mar 2021Cited by 39 (Europe PMC)

PMID33808404 (opens in a new tab)PMCIDPMC8066839 (opens in a new tab)DOI10.3390/biomedicines9040353 (opens in a new tab)PepBankPUB-33808404
Download PDFPubMedAsk about this study
Jump to 12 results

Summary

Dysregulation of glucose homeostasis plays a major role in the pathogenesis of non-alcoholic steatohepatitis (NASH) as it activates proinflammatory and profibrotic processes. Beneficial effects of antiglycemic treatments such as GLP-1 agonist or SGLT-2 inhibitor on NASH in patients with diabetes have already been investigated. However, their effect on NASH in a non-diabetic setting remains unclear. With this aim, we investigated the effect of long-acting GLP1-agonist dulaglutide and SGLT-2 inhibitor empagliflozin and their combination in a non-diabetic mouse model of NASH. C57BL/6 mice received a high-fat-high-fructose (HFHC) diet with a surplus of cholesterol for 16 weeks. After 12 weeks of diet, mice were treated with either dulaglutide, empagliflozin or their combination. Dulaglutide alone and in combination with empagliflozin led to significant weight loss, improved glucose homeostasis and diminished anti-inflammatory and anti-fibrotic pathways. Combination of dulaglutide and empagliflozin further decreased MoMFLy6CHigh and CD4+Foxp3+ T cells. No beneficial effects for treatment with empagliflozin alone could be shown. While no effect of dulaglutide or its combination with empaglifozin on hepatic steatosis was evident, these data demonstrate distinct anti-inflammatory effects of dulaglutide and their combination with empagliflozin in a non-diabetic background, which could have important implications for further treatment of NASH.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study12

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice with NASH, dulaglutide alone led to significant weight loss.

    In plain wordsIn mice with NASH, dulaglutide alone led to significant weight loss.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseBody weight
    Study

    mousen: not reported in source

    Non-diabetic HFHC-induced NASH
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Dulaglutide alone and in combination with empagliflozin led to significant weight loss, improved glucose homeostasis and diminished anti-inflammatory and anti-fibrotic pathways.
    1 context sentence
    Summary · context
    With this aim, we investigated the effect of long-acting GLP1-agonist dulaglutide and SGLT-2 inhibitor empagliflozin and their combination in a non-diabetic mouse model of NASH. C57BL/6 mice received a high-fat-high-fructose (HFHC) diet with a surplus of cholesterol for 16 weeks. After 12 weeks of diet, mice were treated with either dulaglutide, empagliflozin or their combination.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice with NASH, dulaglutide alone improved glucose homeostasis.

    In plain wordsIn mice with NASH, dulaglutide alone improved glucose regulation.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    MixedGlucose homeostasis
    Study

    mousen: not reported in source

    Non-diabetic HFHC-induced NASH
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Dulaglutide alone and in combination with empagliflozin led to significant weight loss, improved glucose homeostasis and diminished anti-inflammatory and anti-fibrotic pathways.
    1 context sentence
    Summary · context
    With this aim, we investigated the effect of long-acting GLP1-agonist dulaglutide and SGLT-2 inhibitor empagliflozin and their combination in a non-diabetic mouse model of NASH. C57BL/6 mice received a high-fat-high-fructose (HFHC) diet with a surplus of cholesterol for 16 weeks. After 12 weeks of diet, mice were treated with either dulaglutide, empagliflozin or their combination.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In mice with NASH, dulaglutide alone diminished anti-inflammatory pathways, as worded in the abstract.

    In plain wordsIn mice with NASH, dulaglutide alone diminished anti-inflammatory pathways, as the abstract states.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseAnti-inflammatory pathways
    Study

    mousen: not reported in source

    Non-diabetic HFHC-induced NASH
    Outcome group
    Receptor activity and mechanism · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Dulaglutide alone and in combination with empagliflozin led to significant weight loss, improved glucose homeostasis and diminished anti-inflammatory and anti-fibrotic pathways.
    1 context sentence
    Summary · context
    With this aim, we investigated the effect of long-acting GLP1-agonist dulaglutide and SGLT-2 inhibitor empagliflozin and their combination in a non-diabetic mouse model of NASH. C57BL/6 mice received a high-fat-high-fructose (HFHC) diet with a surplus of cholesterol for 16 weeks. After 12 weeks of diet, mice were treated with either dulaglutide, empagliflozin or their combination.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In mice with NASH, dulaglutide alone diminished anti-fibrotic pathways, as worded in the abstract.

    In plain wordsIn mice with NASH, dulaglutide alone diminished anti-fibrotic pathways, as the abstract states.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseAnti-fibrotic pathways
    Study

    mousen: not reported in source

    Non-diabetic HFHC-induced NASH
    Outcome group
    Receptor activity and mechanism · Liver
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Dulaglutide alone and in combination with empagliflozin led to significant weight loss, improved glucose homeostasis and diminished anti-inflammatory and anti-fibrotic pathways.
    1 context sentence
    Summary · context
    With this aim, we investigated the effect of long-acting GLP1-agonist dulaglutide and SGLT-2 inhibitor empagliflozin and their combination in a non-diabetic mouse model of NASH. C57BL/6 mice received a high-fat-high-fructose (HFHC) diet with a surplus of cholesterol for 16 weeks. After 12 weeks of diet, mice were treated with either dulaglutide, empagliflozin or their combination.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In mice with NASH, dulaglutide alone had no evident effect on hepatic steatosis.

    In plain wordsIn mice with NASH, dulaglutide alone had no evident effect on liver fat.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeHepatic steatosis
    Study

    mousen: not reported in source

    Non-diabetic HFHC-induced NASH
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated

    Source sentences

    Summary
    While no effect of dulaglutide or its combination with empaglifozin on hepatic steatosis was evident
    1 context sentence
    Summary · context
    With this aim, we investigated the effect of long-acting GLP1-agonist dulaglutide and SGLT-2 inhibitor empagliflozin and their combination in a non-diabetic mouse model of NASH. C57BL/6 mice received a high-fat-high-fructose (HFHC) diet with a surplus of cholesterol for 16 weeks. After 12 weeks of diet, mice were treated with either dulaglutide, empagliflozin or their combination.

Studies that did not test the peptide alone7

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

  1. 06AnimalNot a test of Dulaglutide (Trulicity) aloneAnimal study (in vivo)Efficacy outcome

    In mice with NASH, dulaglutide plus empagliflozin led to significant weight loss.

    In plain wordsIn mice with NASH, dulaglutide plus empagliflozin led to significant weight loss.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseBody weight
    Study

    mousen: not reported in source

    Non-diabetic HFHC-induced NASH
    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    Dulaglutide alone and in combination with empagliflozin led to significant weight loss, improved glucose homeostasis and diminished anti-inflammatory and anti-fibrotic pathways.
    1 context sentence
    Summary · context
    With this aim, we investigated the effect of long-acting GLP1-agonist dulaglutide and SGLT-2 inhibitor empagliflozin and their combination in a non-diabetic mouse model of NASH. C57BL/6 mice received a high-fat-high-fructose (HFHC) diet with a surplus of cholesterol for 16 weeks. After 12 weeks of diet, mice were treated with either dulaglutide, empagliflozin or their combination.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  2. 07AnimalNot a test of Dulaglutide (Trulicity) aloneAnimal study (in vivo)Efficacy outcome

    In mice with NASH, dulaglutide plus empagliflozin improved glucose homeostasis.

    In plain wordsIn mice with NASH, dulaglutide plus empagliflozin improved glucose regulation.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    MixedGlucose homeostasis
    Study

    mousen: not reported in source

    Non-diabetic HFHC-induced NASH
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    Dulaglutide alone and in combination with empagliflozin led to significant weight loss, improved glucose homeostasis and diminished anti-inflammatory and anti-fibrotic pathways.
    1 context sentence
    Summary · context
    With this aim, we investigated the effect of long-acting GLP1-agonist dulaglutide and SGLT-2 inhibitor empagliflozin and their combination in a non-diabetic mouse model of NASH. C57BL/6 mice received a high-fat-high-fructose (HFHC) diet with a surplus of cholesterol for 16 weeks. After 12 weeks of diet, mice were treated with either dulaglutide, empagliflozin or their combination.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  3. 08AnimalNot a test of Dulaglutide (Trulicity) aloneAnimal study (in vivo)Mechanism

    In mice with NASH, dulaglutide plus empagliflozin diminished anti-inflammatory pathways, as worded in the abstract.

    In plain wordsIn mice with NASH, dulaglutide plus empagliflozin diminished anti-inflammatory pathways, as the abstract states.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseAnti-inflammatory pathways
    Study

    mousen: not reported in source

    Non-diabetic HFHC-induced NASH
    Outcome group
    Receptor activity and mechanism · Immune and inflammation

    Source sentences

    Summary
    Dulaglutide alone and in combination with empagliflozin led to significant weight loss, improved glucose homeostasis and diminished anti-inflammatory and anti-fibrotic pathways.
    1 context sentence
    Summary · context
    With this aim, we investigated the effect of long-acting GLP1-agonist dulaglutide and SGLT-2 inhibitor empagliflozin and their combination in a non-diabetic mouse model of NASH. C57BL/6 mice received a high-fat-high-fructose (HFHC) diet with a surplus of cholesterol for 16 weeks. After 12 weeks of diet, mice were treated with either dulaglutide, empagliflozin or their combination.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  4. 09AnimalNot a test of Dulaglutide (Trulicity) aloneAnimal study (in vivo)Mechanism

    In mice with NASH, dulaglutide plus empagliflozin diminished anti-fibrotic pathways, as worded in the abstract.

    In plain wordsIn mice with NASH, dulaglutide plus empagliflozin diminished anti-fibrotic pathways, as the abstract states.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseAnti-fibrotic pathways
    Study

    mousen: not reported in source

    Non-diabetic HFHC-induced NASH
    Outcome group
    Receptor activity and mechanism · Liver

    Source sentences

    Summary
    Dulaglutide alone and in combination with empagliflozin led to significant weight loss, improved glucose homeostasis and diminished anti-inflammatory and anti-fibrotic pathways.
    1 context sentence
    Summary · context
    With this aim, we investigated the effect of long-acting GLP1-agonist dulaglutide and SGLT-2 inhibitor empagliflozin and their combination in a non-diabetic mouse model of NASH. C57BL/6 mice received a high-fat-high-fructose (HFHC) diet with a surplus of cholesterol for 16 weeks. After 12 weeks of diet, mice were treated with either dulaglutide, empagliflozin or their combination.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  5. 10AnimalNot a test of Dulaglutide (Trulicity) aloneAnimal study (in vivo)Mechanism

    In mice with NASH, dulaglutide plus empagliflozin further decreased MoMFLy6C High cells.

    In plain wordsIn mice with NASH, dulaglutide plus empagliflozin further decreased MoMFLy6C High immune cells.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseMoMFLy6C High cells
    Study

    mousen: not reported in source

    Non-diabetic HFHC-induced NASH
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    Combination of dulaglutide and empagliflozin further decreased MoMFLy6CHigh and CD4+Foxp3+ T cells.
    1 context sentence
    Summary · context
    With this aim, we investigated the effect of long-acting GLP1-agonist dulaglutide and SGLT-2 inhibitor empagliflozin and their combination in a non-diabetic mouse model of NASH. C57BL/6 mice received a high-fat-high-fructose (HFHC) diet with a surplus of cholesterol for 16 weeks. After 12 weeks of diet, mice were treated with either dulaglutide, empagliflozin or their combination.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  6. 11AnimalNot a test of Dulaglutide (Trulicity) aloneAnimal study (in vivo)Mechanism

    In mice with NASH, dulaglutide plus empagliflozin further decreased CD4-positive Foxp3-positive T cells.

    In plain wordsIn mice with NASH, dulaglutide plus empagliflozin further decreased CD4-positive Foxp3-positive T cells.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseCD4 Foxp3 T cells
    Study

    mousen: not reported in source

    Non-diabetic HFHC-induced NASH
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    Combination of dulaglutide and empagliflozin further decreased MoMFLy6CHigh and CD4+Foxp3+ T cells.
    1 context sentence
    Summary · context
    With this aim, we investigated the effect of long-acting GLP1-agonist dulaglutide and SGLT-2 inhibitor empagliflozin and their combination in a non-diabetic mouse model of NASH. C57BL/6 mice received a high-fat-high-fructose (HFHC) diet with a surplus of cholesterol for 16 weeks. After 12 weeks of diet, mice were treated with either dulaglutide, empagliflozin or their combination.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  7. 12AnimalNot a test of Dulaglutide (Trulicity) aloneAnimal study (in vivo)Efficacy outcome

    In mice with NASH, dulaglutide plus empagliflozin had no evident effect on hepatic steatosis.

    In plain wordsIn mice with NASH, dulaglutide plus empagliflozin had no evident effect on liver fat.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeHepatic steatosis
    Study

    mousen: not reported in source

    Non-diabetic HFHC-induced NASH
    Outcome group
    Liver fat and liver function · Liver

    Source sentences

    Summary
    While no effect of dulaglutide or its combination with empaglifozin on hepatic steatosis was evident
    1 context sentence
    Summary · context
    With this aim, we investigated the effect of long-acting GLP1-agonist dulaglutide and SGLT-2 inhibitor empagliflozin and their combination in a non-diabetic mouse model of NASH. C57BL/6 mice received a high-fat-high-fructose (HFHC) diet with a surplus of cholesterol for 16 weeks. After 12 weeks of diet, mice were treated with either dulaglutide, empagliflozin or their combination.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.